Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model

Magnetic resonance imaging (MRI) is the most frequently used imaging tool in preoperative staging of endometrial cancer. FDG-PET has demonstrated higher sensitivity than MRI in detecting nodal involvement and metastatic disease and is currently used in adjunction to MRI. Distinct MRI and FDG-PET parameters correlate well with tumor aggressiveness and can and have been used as prognostic factors. The Investigators believe that the combination of data from these two imaging techniques, from which different derived tumor features can be extrapolated, can stratify patients in high-risk and low-risk groups already preoperatively. The aim of combined techniques is to collect large amounts of data leveraging advantages of both modalities (MR's strengths in local staging and PET's strengths in nodal staging) in a single scan from which to extrapolate a preoperative, non-invasive, prognostic model.

Inclusion criteria

• histopathological confirmation of a primary endometrial cancer
• age > 18 years
• no contraindication to surgery (comorbidity, contraindication or lack of consent)
• no contraindication to preoperative imaging
• visible tumor at imaging
• signed inform consent.

Exclusion criteria

• patients unsuitable for surgical intervention (comorbidity, contraindication or lack of consent, poor performance status)
• age < 18 years, c) inability to complete the needed imaging examination (ie, severe claustrophobia)
• any additional medical condition that may significantly interfere with study compliance
• all the contraindication for MRI (ie, pacemaker).